Abstract
No public abstract is available from the verified source records.
P. Corcia, A. Erazo, P. Couratier
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Trial of antisense oligonucleotide tofersen for SOD1 ALS
10.1056/nejmoa2204705 · 2022
Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis
10.1007/s10072-025-07994-2 · 2025
Tofersen treatment in SOD1-ALS: real-world evidence from a retrospective multicenter study in France (FORSLA Study)
10.1016/j.mayocpiqo.2026.100739 · 2026
Tofersen and other antisense oligonucleotides in ALS
10.1177/17562864251313915 · 2025
Long-term tofersen in SOD1 amyotrophic lateral sclerosis
10.1001/jamaneurol.2025.4946 · 2026
Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p. D91A variant in amyotrophic lateral sclerosis patients
10.1038/s43856-024-00573-0 · 2024
Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS – A multicenter observational study over 18 months
10.1002/mus.28182 · 2024
Prevalence of SOD1 and C9orf72 variants among French ALS Population: The GENIALS Study
10.1111/ene.70302 · 2025
No additional external references are available.